Nuevo medicamento parq dermatitis atopica aprobado por la FDA.

Injectable Dupilumab Approved for Eczema

By Kelly Young

Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM

The FDA has approved dupilumab (Dupixent) to treat moderate-to-severe atopic dermatitis. It is indicated in adults whose eczema isn't well controlled by topical treatments or who can't use such treatments. The drug's list price is $37,000 per year, the New York Times reports.

The injectable human monoclonal antibody works by attaching to an inflammation-causing protein — interleukin-4 receptor alpha subunit. In two trials, skin clearance was more common among those given dupilumab than those who received placebo (37% vs. 10%) after 16 weeks of treatment.

Side effects include serious allergic reactions, conjunctivitis, and keratitis. Some of the more common adverse events include injection site reactions, cold sores around the mouth, and inflammation of the eye and eyelid.

FDA news release (Free)

New York Times story (Free)

Background: NEJM Journal Watch Dermatology coverage of dupilumab for atopic dermatitis (Your NEJM Journal Watch registration required)

Benjamin Hidalgo-Matlock

Skin Care Physicians of Costa Rica

4000-1054

2208-8206

Please excuse the shortness of this message, as it has been sent from a mobile device.